01:54 PM EST, 01/13/2025 (MT Newswires) -- Eli Lilly ( LLY ) expects its experimental weight-loss pill, orforglipron, to receive approval by early 2026, Bloomberg reported Monday, citing Chief Executive Dave Ricks.
The drugmaker anticipates receiving data on the pill before mid-2025, potentially leading to approval the following year, Ricks said in an interview with Bloomberg TV.
The pill could offer a more convenient and scalable alternative to injectable weight-loss drugs, which have faced supply issues due to production constraints, Ricks said.
Eli Lilly ( LLY ) didn't immediately respond to a request for comment from MT Newswires.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 796.68, Change: -3.22, Percent Change: -0.40